Avanos Medical Inc (AVNS)

Fixed asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 687,800 681,500 682,400 680,100 705,700 749,900 780,700 814,300 820,000 795,900 777,900 761,300 744,600 736,200 737,800 715,100 714,800 719,600 705,300 713,800
Property, plant and equipment US$ in thousands 143,900 122,600 163,500 163,900 163,400 198,200 166,900 168,100 169,700 214,800 173,400 175,300 177,300 179,300 178,700
Fixed asset turnover 5.21 6.37 4.98 5.00 4.87 3.92 4.56 4.43 4.34 3.43 4.12 4.08 4.06 3.93 3.99

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $687,800K ÷ $—K
= —

The fixed asset turnover ratio of Avanos Medical Inc has exhibited fluctuations over the past few years. The ratio measures the efficiency of the company in generating revenue from its investment in fixed assets.

From March 2020 to June 2022, the fixed asset turnover ratio ranged between 3.93 and 4.56, indicating that for every dollar invested in fixed assets, the company generated between $3.93 and $4.56 in sales revenue. This suggests that Avanos was effectively utilizing its fixed assets to generate revenue during this period.

In the subsequent periods, the ratio showed more variability, with a notable decline to 3.43 in June 2021 before rebounding to 6.37 in June 2023. The sharp increase in June 2023 signifies a significant improvement in the efficiency of utilizing fixed assets to generate revenue.

As of the latest available data in December 2023, the fixed asset turnover ratio stood at 5.21, demonstrating continued efficiency in asset utilization. However, data is missing for the following periods, making it difficult to assess the trend beyond 2023.

Overall, the analysis of Avanos Medical Inc's fixed asset turnover indicates fluctuations in the company's ability to generate sales from its investment in fixed assets, with periods of both efficiency and volatility.